Guggenheim Maintains Buy on Summit Therapeutics, Lowers Price Target to $38

Benzinga · 2d ago
Guggenheim analyst Brad Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $40 to $38.